Peptides in the United States

The United States peptide landscape changed dramatically in 2025-2026. The FDA's compounding rules now allow several peptides previously restricted to research-only status to be compounded through licensed 503A and 503B pharmacies with a valid prescription.

Currently FDA-approved peptides (prescription only): Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound), Sermorelin, Teduglutide (Gattex/GLP-2), Elamipretide (SS-31, for Barth syndrome), and Bremelanotide (Vyleesi/PT-141).

Compoundable through licensed pharmacies: BPC-157, TB-500, CJC-1295, Ipamorelin, Selank, Semax, Thymosin Alpha-1, GHK-Cu (injectable), and others. Availability depends on whether the peptide appears on the FDA's bulk drug substance lists for compounding.

Sold as "research compounds": Most other peptides, including Epithalon, MOTS-c, Humanin, Dihexa, Retatrutide. These are legal to purchase from research chemical suppliers as long as they are not marketed for human consumption.

State-by-state laws vary slightly. California, New York, and Florida have the strictest enforcement on practitioner advertising. Texas, Tennessee, and Arizona are friendlier to compounding clinics. The DEA does not schedule any of these peptides federally.

The US has the world's most developed peptide market. Three sourcing routes matter for most users:

• Compounding pharmacies (503A) — Telehealth platforms like Henry Meds, Hims, Mochi, and Fella connect you with a prescribing physician, then ship compounded peptides directly. Prices: Semaglutide $200-400/mo, BPC-157 stack $150-300/mo.
• Licensed anti-aging clinics — In-person clinics in major cities offer peptide protocols with bloodwork. Higher cost but supervised. Common in Miami, Austin, Scottsdale, Los Angeles, Dallas.
• Research peptide suppliers — Sites like Peptide Sciences, Bio-Peptide, Limitless Life, and Sports Technology Labs sell research-grade peptides domestically. Always third-party tested via Janoshik or MZ Biolabs. Shipping is typically 2-5 days.

For the compounding route, you still need a prescription. Most telehealth platforms include the consult and prescription in their monthly fee. For research peptides, you self-administer at your own risk and must not market them for human consumption.

US users have full access to consumer genetic testing — no DTC restrictions like in France or Germany. Most Americans already have 23andMe or AncestryDNA data sitting in their account, which you can upload to PeptidesDNA for $99.

This matters because the US peptide market is also the most expensive. A 6-month Semaglutide protocol can cost $1,500-3,000. A BPC-157 stack runs $900-1,800. Knowing in advance whether your genetics predict you to be a responder or non-responder saves significant money.

Three examples relevant to US users specifically:

• Semaglutide non-response is genetic. A 2025 study found people with certain GLP-1 receptor variants lose weight 58% faster than non-carriers at the same dose. Two of the three variants are common in US populations.
• BPC-157 efficacy varies by collagen genetics. If you carry the COL5A1 variant linked to soft tissue vulnerability, BPC-157 is one of the strongest peptides for you. If not, you may see minimal benefit.
• CYP enzyme variants affect peptide dosing. CYP2C19 intermediate metabolizers (about 30% of Americans of European descent) clear certain compounds slower, meaning standard doses can accumulate.

The US peptide market in 2026

The United States is the world's largest peptide market by both volume and dollar value. The combination of FDA compounding pathways, a strong biohacking community, high disposable income for health spending, and the GLP-1 weight loss boom has created an ecosystem unlike anywhere else.

Semaglutide and Tirzepatide alone now represent over $50 billion in annual sales. Compounded versions through telehealth platforms have democratized access for patients without insurance coverage. At the same time, research peptide suppliers ship millions of vials of BPC-157, TB-500, GHK-Cu, and others to US addresses every month.

The FDA compounding shift

For years, the FDA classified most peptides as research-only. In late 2024 and through 2025-2026, that changed. Several peptides — most notably BPC-157 — moved from the "do not compound" list into the regulated 503A/503B compounding pathway. This means a US patient can now legally obtain BPC-157 with a prescription, compounded by a licensed pharmacy, in clinical-grade purity.

Not every peptide made the list. Epithalon, MOTS-c, Humanin, Dihexa, and most experimental peptides remain "research only" — meaning they are not legally available for human use through approved channels. You can still purchase them from research chemical suppliers, but with no medical oversight and no guarantee of purity beyond third-party testing.

Why US peptide users should test their DNA first

Three reasons specifically matter in the US context:

Cost. A year of Semaglutide through telehealth is $2,400-4,800. Six months of a BPC-157 + TB-500 protocol is $900-1,800. Even a single GHK-Cu protocol is several hundred dollars. Knowing whether your genetics predict response before you commit saves real money.

Stacking complexity. US biohackers tend to stack aggressively — Wolverine stacks, cognitive stacks, GLP-1 + Sermorelin combinations. Genetics determines which combinations actually synergize for you versus duplicating effects.

Compounding pharmacy choice. The compounding pathway only makes sense if the peptide is genuinely matched to your biology. Otherwise you're paying $200-400/month for a compound your body cannot fully use.

Notable peptides for the US market

Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound) — FDA-approved for type 2 diabetes and obesity. Compounded versions widely available through telehealth. Best-studied pharmacogenomics of any peptide. Why some people lose 20% on semaglutide and others lose 5%.

BPC-157 — Now compoundable in the US. Most popular peptide for soft tissue and gut healing. Healed tendons in 8 weeks in animal studies — but not everyone responds the same.

TB-500 — Often stacked with BPC-157 for the "Wolverine Stack." Wolverine stack guide.

GHK-Cu — Used in both injectable peptide protocols and topical skincare. The copper tripeptide modulates thousands of genes related to skin and tissue repair. How GHK-Cu works.

CJC-1295 + Ipamorelin — The classic growth hormone stack used in anti-aging clinics throughout the US. Ipamorelin vs CJC-1295: which one matches your genetics.

Selank and Semax — Russian nootropic peptides, available through US research peptide suppliers and a small number of compounding pharmacies. Selank for anxiety.

State-by-state considerations

Peptides are not scheduled under the Controlled Substances Act, so federal law applies uniformly. However, state regulations affect practitioner behavior:

Texas, Tennessee, Arizona, Nevada, Florida — Friendly to compounding clinics. Many of the largest peptide telehealth platforms are headquartered in these states.

California, New York, Massachusetts — Stricter enforcement on practitioner advertising. Telehealth still operates, but advertising claims face more scrutiny.

Sports/athletic restrictions — TB-500 is banned by WADA, NCAA, MLB, NFL, and most pro sports leagues. BPC-157 is on the WADA monitoring list. If you are tested, do not use either.

Insurance and HSA/FSA coverage

FDA-approved peptides (Semaglutide, Tirzepatide, Sermorelin, etc.) are sometimes covered by insurance for approved indications — primarily diabetes and severe obesity. Most weight-loss prescriptions are still cash-pay, but coverage is expanding in 2026.

Compounded peptides are almost never covered by insurance. They are typically HSA/FSA eligible when prescribed for a documented medical condition. PeptidesDNA genetic reports (the $99 upload and the $299 kit) qualify as HSA/FSA eligible health-related expenses in most cases.